Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiponectin | 3 | 2017 | 59 | 0.810 |
Why?
|
| Peptide Library | 4 | 2014 | 28 | 0.680 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 436 | 0.610 |
Why?
|
| Bacteriophages | 5 | 2013 | 44 | 0.600 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 16 | 0.550 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2017 | 3 | 0.530 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2017 | 5 | 0.530 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 1723 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 154 | 0.500 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 296 | 0.480 |
Why?
|
| Liposomes | 4 | 2011 | 132 | 0.480 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 277 | 0.430 |
Why?
|
| Nanomedicine | 2 | 2014 | 52 | 0.430 |
Why?
|
| Viral Fusion Proteins | 2 | 2011 | 5 | 0.420 |
Why?
|
| Adipocytes | 2 | 2017 | 60 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 218 | 0.350 |
Why?
|
| Viral Proteins | 1 | 2013 | 190 | 0.340 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 1019 | 0.330 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 53 | 0.330 |
Why?
|
| Oligopeptides | 1 | 2010 | 109 | 0.320 |
Why?
|
| Nanoparticles | 2 | 2013 | 460 | 0.310 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2006 | 10 | 0.250 |
Why?
|
| Endothelin-1 | 1 | 2006 | 57 | 0.240 |
Why?
|
| Actins | 1 | 2006 | 164 | 0.230 |
Why?
|
| Cell Line, Tumor | 7 | 2014 | 2676 | 0.220 |
Why?
|
| Neoplasms | 3 | 2024 | 1377 | 0.210 |
Why?
|
| Pancreatic Cyst | 1 | 2023 | 7 | 0.200 |
Why?
|
| Pancreas | 1 | 2023 | 45 | 0.200 |
Why?
|
| Doxorubicin | 3 | 2014 | 97 | 0.200 |
Why?
|
| Protein Transport | 3 | 2014 | 296 | 0.200 |
Why?
|
| 3T3-L1 Cells | 2 | 2017 | 18 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 79 | 0.190 |
Why?
|
| Space Flight | 1 | 2022 | 17 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 30 | 0.180 |
Why?
|
| Weightlessness | 1 | 2022 | 27 | 0.180 |
Why?
|
| Capsid Proteins | 3 | 2012 | 76 | 0.180 |
Why?
|
| Thrombosis | 1 | 2022 | 81 | 0.170 |
Why?
|
| Dog Diseases | 1 | 2021 | 49 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 415 | 0.150 |
Why?
|
| Ultrasonography | 3 | 2024 | 135 | 0.150 |
Why?
|
| Drug Carriers | 2 | 2011 | 174 | 0.150 |
Why?
|
| Humans | 15 | 2024 | 43102 | 0.150 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 1180 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1542 | 0.130 |
Why?
|
| Thiazolidines | 1 | 2017 | 4 | 0.130 |
Why?
|
| Female | 10 | 2024 | 24698 | 0.130 |
Why?
|
| Biological Transport | 1 | 2017 | 204 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2006 | 2157 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2022 | 518 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 237 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 968 | 0.120 |
Why?
|
| Hep G2 Cells | 2 | 2013 | 63 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 506 | 0.120 |
Why?
|
| Blotting, Western | 3 | 2013 | 883 | 0.110 |
Why?
|
| Mice | 4 | 2017 | 6644 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1124 | 0.100 |
Why?
|
| Dogs | 2 | 2021 | 204 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2014 | 219 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 108 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2017 | 1621 | 0.100 |
Why?
|
| Particle Size | 2 | 2011 | 272 | 0.100 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 61 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 161 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2013 | 165 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 256 | 0.090 |
Why?
|
| Animals | 6 | 2021 | 16992 | 0.090 |
Why?
|
| Peptides | 2 | 2012 | 372 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1455 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 307 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 458 | 0.090 |
Why?
|
| Immunomagnetic Separation | 1 | 2010 | 4 | 0.080 |
Why?
|
| Static Electricity | 1 | 2010 | 86 | 0.080 |
Why?
|
| Magnetics | 1 | 2010 | 43 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 141 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 63 | 0.080 |
Why?
|
| Apoptosis | 1 | 2017 | 1568 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 154 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 136 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2010 | 273 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 592 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 561 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2010 | 735 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2006 | 456 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 11 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 81 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 20 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 440 | 0.050 |
Why?
|
| Jugular Veins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Astronauts | 1 | 2022 | 6 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1410 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 245 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 293 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1092 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 509 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 378 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 678 | 0.040 |
Why?
|
| Mass Screening | 1 | 2024 | 541 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1271 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2012 | 49 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 144 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 64 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 45 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 20 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 109 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 210 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 347 | 0.020 |
Why?
|
| Freeze Fracturing | 1 | 2010 | 7 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 129 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 160 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 206 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 145 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2011 | 93 | 0.020 |
Why?
|
| Rhodamines | 1 | 2010 | 22 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 184 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 256 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 70 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2007 | 18 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 272 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 652 | 0.010 |
Why?
|
| Axilla | 1 | 2003 | 6 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 28 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 59 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 611 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 1600 | 0.010 |
Why?
|
| Male | 2 | 2010 | 23409 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 2853 | 0.010 |
Why?
|
| Aged | 1 | 2003 | 8214 | 0.010 |
Why?
|
| Middle Aged | 1 | 2003 | 12222 | 0.000 |
Why?
|
| Adult | 1 | 2003 | 13872 | 0.000 |
Why?
|